H.C. Wainwright analyst Michael King maintained a Buy rating on Intellia Therapeutics (NASDAQ:NTLA) on Monday, setting a price target of $171, which is approximately 11.76% above...
I’m writing you today with a big smile on my face. Because humanity just achieved a MONUMENTAL scientific breakthrough. This breakthrough will save sick children and unite broken...
The market may be pretty slow right now, but totals for the first half and second quarter show that stocks have actually been on a tear for most of 2021. Furthermore, those...
Recent days brought new all-time-highs to the S&P 500 and NASDAQ 100, which are up about 14% and 12%, respectively, in 2021. Meanwhile, the Dow Jones Industrial Average, which...
Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company's subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.